Kiora Pharmaceuticals to Webcast On-Demand Presentation at The H.C. Wainwright 27th Annual Global Investment Conference
Kiora Pharmaceuticals (NASDAQ:KPRX) announced that CFO Melissa Tosca will present the company's pipeline of therapies for inherited and inflammatory retinal diseases at the upcoming H.C. Wainwright 27th Annual Global Investment Conference.
The presentation is scheduled for September 5th, 2025, at 7:00 am EDT. Investors can access the presentation through the company's investor relations website, where it will remain available on-demand for 90 days.
Kiora Pharmaceuticals (NASDAQ:KPRX) ha annunciato che la CFO Melissa Tosca presenterà il portafoglio di terapie dell'azienda per le malattie retiniche ereditarie e infiammatorie al H.C. Wainwright 27th Annual Global Investment Conference.
La presentazione è programmata per il 5 settembre 2025 alle 7:00 EDT. Gli investitori potranno visualizzare la presentazione sul sito investor relations dell'azienda, dove rimarrà disponibile on-demand per 90 giorni.
Kiora Pharmaceuticals (NASDAQ:KPRX) anunció que la directora financiera Melissa Tosca presentará la cartera de terapias de la compañía para enfermedades retinianas hereditarias e inflamatorias en la H.C. Wainwright 27th Annual Global Investment Conference.
La presentación está programada para el 5 de septiembre de 2025 a las 7:00 EDT. Los inversores podrán acceder a la presentación a través del sitio web de relaciones con inversores de la compañía, donde permanecerá disponible bajo demanda durante 90 días.
Kiora Pharmaceuticals (NASDAQ:KPRX)는 최고재무책임자 멜리사 토스카가 H.C. Wainwright 제27회 연례 글로벌 투자 컨퍼런스에서 유전성 및 염증성 망막 질환을 위한 회사의 치료 파이프라인을 발표할 것이라고 발표했습니다.
발표 일정은 2025년 9월 5일 오전 7:00 EDT입니다. 투자자들은 회사의 투자자 관계 웹사이트를 통해 발표를 시청할 수 있으며, 해당 자료는 90일 동안 온디맨드로 제공됩니다.
Kiora Pharmaceuticals (NASDAQ:KPRX) a annoncé que la directrice financière Melissa Tosca présentera le portefeuille de thérapies de la société pour les maladies rétiniennes héréditaires et inflammatoires lors de la H.C. Wainwright 27th Annual Global Investment Conference.
La présentation aura lieu le 5 septembre 2025 à 7h00 EDT. Les investisseurs pourront consulter la présentation via le site web des relations investisseurs de la société, où elle restera disponible à la demande pendant 90 jours.
Kiora Pharmaceuticals (NASDAQ:KPRX) gab bekannt, dass CFO Melissa Tosca die Pipeline des Unternehmens für vererbbare und entzündliche Netzhauterkrankungen auf der H.C. Wainwright 27th Annual Global Investment Conference vorstellen wird.
Die Präsentation ist für den 5. September 2025 um 7:00 Uhr EDT angesetzt. Anleger können die Präsentation über die Investor-Relations-Website des Unternehmens aufrufen, wo sie für 90 Tage on-demand verfügbar sein wird.
- None.
- None.
Encinitas, California--(Newsfile Corp. - September 4, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that its Chief Financial Officer, Melissa Tosca, CPA, will showcase the Company's pipeline of therapies targeting inherited and inflammatory retinal diseases at the H.C. Wainwright 27th Annual Global Investment Conference.
Presentation Details
| Date: | Friday, September 5th, 2025 |
| Time: | 7:00 am Eastern Daylight Time |
| Link: | https://ir.kiorapharma.com/news-events/events |
The replay will be available on-demand for 90 days on Kiora's investor relations website.
About Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. We target critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of retinal inflammation. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH).
In addition to news releases and SEC filings, we expect to post information on our website, www.kiorapharma.com, and social media accounts that could be relevant to investors. We encourage investors to follow us on X and LinkedIn as well as to visit our website and/or subscribe to email alerts.
Contact:
investors@kiorapharma.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/265030
FAQ
When is Kiora Pharmaceuticals (KPRX) presenting at the H.C. Wainwright Conference?
Who will present for Kiora Pharmaceuticals at the H.C. Wainwright Conference?
What topics will Kiora Pharmaceuticals (KPRX) cover at the H.C. Wainwright Conference?
How can investors access Kiora Pharmaceuticals' H.C. Wainwright Conference presentation?
